JPRN-jRCT2033210163招募中1 期
A phase I/II study of human induced Pluripotent Stem (iPS) cell-derived cardiomyocyte spheroids in patients with severe heart failure, secondary to ischemic heart disease, undergoing coronary artery bypass grafting - LAPiS Study
Kaneko Takehiko0 个研究点目标入组 10 人开始时间: 2021年6月23日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •Patients with ischemic heart disease undergoing CABG
- •Patients with resting left ventricular ejection fraction (from 0.15 to 0.40) based on institutional assessment on either screening cardiac MRI or echocardiographic assessment
- •New York Heart Association Class II, III or IV
排除标准
- •Patients who are candidates for cardiovascular surgery other than CABG (such as valvular heart surgery)
- •Patients with the following complications
- •Pulmonary hypertension, hypertension, diabetes, liver dysfunction, liver dysfunction, gait disturbance, active infection, active bleeding
研究者
相似试验
已完成
1 期
Clinical trial of human (allogeneic) induced pluripotent stem cell-derived cardiomyocyte sheet for severe cardiomyopathyIschemic cardiomyopathyJPRN-UMIN000032989Osaka University3
招募中
不适用
Establishment and analyses of induced pluripotent stem (iPS) cells / human-induced neuronal (hiN) cells / induced microglia-like (iMG) cells from tissue, to elucidate the pathogenesis and pathophysiology of mental and developmental disorders.Multifactorial psychiatric disorders including schizophrenia, depression, bipolar disorders, neurocognitive disorders, eating disorders, anxiety disorders, sleep disorders and autism spectrum disordersJPRN-UMIN000020468Department of Psychiatry, Nagoya University, Graduate School of Medicine30
招募中
1 期
Phase I, Two-Part, Multi-Center, First-in-Human Study of DS-6000a in Subjects with Advanced Renal Cell Carcinoma and Ovarian TumorsAdvanced Renal Cell Carcinoma and Ovarian TumorsJPRN-jRCT2031220075Inoguchi Akihiro140
尚未招募
1 期
A Phase 1/2a, First-In-Human, Single and Multiple Ascending Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of Intralesional FLD-103 in Subjects with Basal Cell Carcinoma (BCC)Cancer - Non melanoma skin cancerBasal Cell CarcinomaACTRN12624001138572Feldan Therapeutics18
招募中
1 期
Phase I/II, Two-Part, Multicenter First-in-Human Study of DS-7300a in Subjects with Advanced Solid Malignant TumorsJPRN-jRCT2080224907DAIICHI SANKYO Co.,Ltd.180